...
首页> 外文期刊>Frontiers in Bioengineering and Biotechnology >Tailored Cytokine Optimization for ex vivo Culture Platforms Targeting the Expansion of Human Hematopoietic Stem/Progenitor Cells
【24h】

Tailored Cytokine Optimization for ex vivo Culture Platforms Targeting the Expansion of Human Hematopoietic Stem/Progenitor Cells

机译:针对人造造血干/祖细胞的扩增的前体内培养平台的量身定制的细胞因子优化

获取原文

摘要

Umbilical cord blood (UCB) has been established as an alternative source for hematopoietic stem/progenitor cells (HSPC) for cell and gene therapies. Limited cell yields of UCB units have been tackled with the development of cytokine-based ex vivo expansion platforms. To improve the effectiveness of these platforms, namely targeting clinical approval, in this study, we optimized the cytokine cocktails in two clinically relevant expansion platforms for HSPC, a liquid suspension culture system (CS_HSPC) and a co-culture system with bone marrow derived mesenchymal stromal cells (BM MSC) (CS_HSPC/MSC). Using a methodology based on experimental design, three different cytokines (stem cell factor (SCF), fms-like tyrosine kinase 3 ligand (Flt-3L) and thrombopoietin (TPO)) were studied in both systems during a 7-day culture under serum-free conditions. Proliferation and colony-forming unit assays, as well as immunophenotypic analysis were performed. Five experimental outputs (fold increase (FI) of total nucleated cells (FI TNC), FI of CD34+ cells, FI of erythroid burst-forming unit (BFU-E), FI of colony-forming unit granulocyte-monocyte (CFU-GM) and FI of multilineage colony-forming unit (CFU-Mix)) were followed as target outputs of the optimization model. The novel optimized cocktails determined herein comprised concentrations of 64, 61 and 80 ng/mL (CS_HSPC) and 90, 82 and 77 ng/mL (CS_HSPC/MSC) for SCF, Flt-3L and TPO, respectively. After cytokine optimization, CS_HSPC and CS_HSPC/MSC were directly compared as platforms. CS_HSPC/MSC outperformed the feeder-free system in 6 of 8 tested experimental measures, displaying superior capability towards increasing the number of hematopoietic cells while maintaining the expression of HSPC markers (i.e. CD34+ and CD34+CD90+) and multilineage differentiation potential. A tailored approach towards optimization has made it possible to individually maximize cytokine contribution in both studied platforms. Consequently, cocktail optimization has successfully led to an increase in the expansion platform performance, while allowing a rational side-by-side comparison among different platforms and enhancing our knowledge on the impact of cytokine supplementation on the HSPC expansion process.
机译:脐带血(UCB)已被建立为造血茎/祖细胞(HSPC)的替代来源,用于细胞和基因疗法。有限的UCB单元的细胞产量与基于细胞因子的离体膨胀平台的开发进行了解决。为了提高这些平台的有效性,即靶向临床批准,在本研究中,我们优化了Hspc,液体悬浮培养系统(CS_hspc)和骨髓衍生间充质的临床相关扩展平台中的细胞因子鸡尾酒。基质细胞(BM MSC)(CS_HSPC / MSC)。在血清下的7天培养期间,在两种系统中使用了基于实验设计的三种不同细胞因子(干细胞因子(SCF),FMS样酪氨酸激酶3配体(FLT-3L)和血小板生成素(TPO)。 - 免费条件。进行增殖和菌落形成单元测定以及免疫胞间型分析。五个实验输出(折叠增加(FI)总核细胞(FI TNC),CD34 +细胞的FI,红润突发成形单元(BFU-E),集核心形成单位粒细胞单核细胞(CFU-GM)遵循多重菌落形成单位(CFU-MIX))作为优化模型的目标输出。本文确定的新型优化的鸡尾酒在本文中确定了SCF,FLT-3L和TPO的64,61和80ng / mL(CS_HSPC)和90,82和77ng / mL(CS_HSPC / MSC)。细胞因子优化后,CS_HSPC和CS_HSPC / MSC直接与平台进行比较。 CS_HSPC / MSC在8个测试的实验措施中表现出无成馈系统,在保持造血细胞的数量的同时,在保持HSPC标记的表达(即CD34 +和CD34 + CD90 +)和多线性分化潜力的同时,显示出血管生成细胞数量的优异能力。定制的优化方法使得可以单独地最大化研究两者的细胞因子贡献。因此,鸡尾酒优化已成功导致扩展平台性能的增加,同时允许不同平台的合理并排比较,并提高了我们对细胞因子补充对HSPC扩展过程的影响的知识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号